ストックスクリーナーアプリを入手
6.15
4.80%
-0.31
アフターアワーズ：
6.16
0.010
+0.16%
前日終値:
$6.46
開ける：
$6.46
24時間の取引高:
945.89K
Relative Volume:
0.55
時価総額：
$523.57M
収益：
$11.40B
当期純損益:
$-95.73M
株価収益率:
-2.5102
EPS:
-2.45
ネットキャッシュフロー:
$-64.37M
1週間 パフォーマンス:
-11.26%
1か月 パフォーマンス:
+8.27%
6か月 パフォーマンス:
-27.56%
1年 パフォーマンス:
-32.57%
1日の値動き範囲:
$6.03
$6.5253
1週間の範囲:
$6.03
$6.9096
52週間の値動き範囲:
$4.70
$10.44
Mind Medicine Inc Stock (MNMD) Company Profile
MNMD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MNMD
Mind Medicine Inc
|
6.15 | 523.57M | 11.40B | -95.73M | -64.37M | -2.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-28 | 開始されました | Evercore ISI | Outperform |
| 2024-12-20 | 開始されました | Chardan Capital Markets | Buy |
| 2024-10-14 | 再開されました | Leerink Partners | Outperform |
| 2024-07-24 | 開始されました | ROTH MKM | Buy |
| 2024-05-29 | 開始されました | Robert W. Baird | Outperform |
| 2024-04-15 | 開始されました | Leerink Partners | Outperform |
| 2023-12-05 | 開始されました | Canaccord Genuity | Buy |
| 2022-12-09 | 再開されました | ROTH Capital | Buy |
| 2022-11-16 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-08-26 | 開始されました | Oppenheimer | Outperform |
| 2022-08-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-05-04 | 開始されました | ROTH Capital | Buy |
| 2021-06-28 | 開始されました | Maxim Group | Buy |
すべてを表示
Mind Medicine Inc (MNMD) 最新ニュース
Psychedelic: Compass, GH Research, MindMed report quarterly earnings - Yahoo Finance
Mind Medicine (MNMD) Rating and Price Target Maintained by Chardan Capital | MNMD Stock News - GuruFocus
Rising Leaders 2025: Rob Barrow On Leading MindMed’s Psychedelic Renaissance - insights.citeline.com
Mind Medicine Inc (MNMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amidst Financial ... - Yahoo Finance
Mind Medicine Inc (MNMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amidst Financial Challenges - GuruFocus
MindMed Advances Phase 3 Trials for Brain Health - TipRanks
Transcript : Mind Medicine Inc., Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
MindMed Advances Phase 3 Trials for Brain Health Treatments - TipRanks
MindMed Q1 2025 slides: Phase 3 trials advance as cash position remains strong - Investing.com Australia
Earnings call transcript: MindMed Q1 2025 results show mixed signals By Investing.com - Investing.com UK
MindMed (MNMD) Advances Phase 3 Trials with Growing Enthusiasm | MNMD Stock News - GuruFocus
Mind Medicine (MindMed) Inc. SEC 10-Q Report - TradingView
MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates - The Joplin Globe
(MNMD) Long Term Investment Analysis - news.stocktradersdaily.com
MindMed to Report First Quarter 2025 Financial Results on May 8, 2025 | MNMD Stock News - GuruFocus
Great week for Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) institutional investors after losing 28% over the previous year - simplywall.st
MindMed to Report First Quarter 2025 Financial Results on May 8, 2025 - Business Wire
Mind Medicine: Strong Data, But Psychedelic Stigma Still Clouds Investor Confidence - Seeking Alpha
Institutional investors own a significant stake of 50% in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Yahoo Finance
Mind Medicine (Mindmed) IncMindmed Enters Into First Amendment To Loan And Security AgreementSEC Filing - marketscreener.com
MindMed Announces New Employee Inducement Grants | MNMD Stock Ne - GuruFocus
MindMed Announces New Employee Inducement Grants | MNMD Stock News - GuruFocus
MindMed Announces New Employee Inducement Grants - Business Wire
Lobbying Update: $100,000 of MIND MEDICINE (MINDMED) INC. lobbying was just disclosed - Nasdaq
Mind Medicine: Initiating Hold Rating Due To Regulatory Challenges (NASDAQ:MNMD) - Seeking Alpha
How the (MNMD) price action is used to our Advantage - news.stocktradersdaily.com
Broadway Gold Mining : MindMed Promotes Jeanne Bonelle to Executive Vice President, Technical Operations - marketscreener.com
MindMed Begins Phase 3 Study of MM120 for Major Depressive Disorder - TipRanks
Oppenheimer maintains MindMed stock Outperform with $20 target By Investing.com - Investing.com India
MindMed launches phase 3 LSD study for depression By Investing.com - Investing.com Nigeria
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD) - GuruFocus
MindMed launches phase 3 LSD study for depression - Investing.com Australia
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of - GuruFocus
Mindmed Announces First Patient Dosed In Phase 3 Emerge Study Of Mm120 In Major Depressive Disorder (Mdd) - marketscreener.com
Breakthrough: First-Ever Phase 3 LSD Depression Trial Begins at MindMed - Stock Titan
MindMed Appoints Schond L. Greenway as Chief Financial Officer - MarketScreener
MNMD stock touches 52-week low at $5.03 amid market challenges - Investing.com India
Long Term Trading Analysis for (MNMD) - news.stocktradersdaily.com
MNMD stock touches 52-week low at $5.03 amid market challenges By Investing.com - Investing.com South Africa
MNMD Stock Forecast From 2025 To 2040 - Exla Resources
Mind Medicine CEO Robert Barrow sells shares worth $142,941 By Investing.com - Investing.com India
MindMed Advances Clinical Programs with Strong Financial Backing - TipRanks
Mind Medicine CEO Robert Barrow sells shares worth $142,941 - Investing.com
MindMed Strengthens Brain Health Pipeline with Key Technical Talent Acquisition - Stock Titan
Generalized Anxiety Disorder Treatment Market Size in 7MM - openPR
MindMed appoints new Chief Commercial Officer By Investing.com - Investing.com South Africa
MindMed Appoints Matt Wiley as Chief Commercial Officer - Quantisnow
MindMed appoints new Chief Commercial Officer - Investing.com
Mind Medicine Inc (MNMD) 財務データ
収益
当期純利益
現金流量
EPS
0.84%
0.15%
大文字化:
|
ボリューム (24 時間):